REFERENCES
- Mohammadian S, Bazrafshan H R, Sadeghi-Nejad A. Endocrine gland abnormalities in thalassemia major: a brief review. J Pediatr Endocrinol Metab 2003; 16: 957–964
- Schnedl W J, Lahousen T, Wallner S J, Krause R, Lipp R W. Silent hemoglobin variants and determination of HbA(1c) with the high-resolution program of the HPLC HA-8160 hemoglobin analyzer. Clin Biochem 2005; 38: 88–91
- Weykamp C W, Penders T J, Muskiet F A, Van Der Slik W. Influence of hemoglobin variants and derivatives on glycol-hemoglobin determinations, as investigated by 102 laboratories using 16 methods. Clin Chem. 1993; 39: 1717–1723
- Kosecki S M, Rodgers P T, Adams M B. Glycemic monitoring in diabetics with sickle cell plus beta-thalassemia hemoglobinopathy. Ann Pharmacother. 2005; 39: 1557–60, Epub 2005 Aug 2
- Al-Fadhli S M, Ahmad A A, Al-Jafar H A. Effect of sickle cell trait and β-thalassemia minor on determinations of HbA1c by an immunoassay method. Saudi Med J 2001; 22: 686–689
- Chen H S, Chen R L, Chang Z Y, Li H D. A comparison of fructosamine and HbA1c for home self-monitoring blood glucose levels in type 2 diabetes. Zhonghua Yi Xue Za Zhi (Taipei) 2002; 65: 151–155
- Edelman S V, Bell J M, Serrano R B, Kelemen D. Home testing of fructosamine improves glycemic control in patients with diabetes. Endocr Pract 2001; 7: 454–458
- , et al. Mastrototaro JJ. The MiniMed continuous glucose monitoring system. J Pediatr Endocrinol Metab 1999; 12: 751–758
- Gross T M, Bode B W, Einhorn D, et al. Performance evaluation of the MiniMed continuous glucose monitoring system during patient home use. Diabetes Technol Therapeut 2000; 2: 67–74
- Gross T M, ter Veer A, Spell J, Mastrototaro J M. Continuous glucose monitoring in previously unstudied populations. Diabetes 2000; 49(Suppl 1)A440
- Gibson L C, Halvorson M J, Carpenter S, Kaufman R. Short-term use of the MiniMed continuous monitoring system to determine patterns of glycemia in pediatric patients with type 1 DM. Diabetes 2000; 49(Suppl 1)A438
- Boland E A, Delucia M, Brandt C A, Grey M J, Tamborlane W V. Limitations of conventional methods of self blood glucose monitoring: lessons learned from three days of continuous glucose monitoring (CGMS) in pediatric patients with type 1 diabetes. Diabetes 2000; 49(Suppl 1)A397
- Sabbah H, McCulloch K, Fredrickson L P, Gross T M, Bode B W. Detailed data from a continuous glucose monitoring system (CGMS) facilitates comprehensive diabetes management recommendations. Diabetes 2000; 49(Suppl 1)A718
- Bode B W, Gross T M, Thornton K R, Mastrototaro J J. Continuous glucose monitoring facilitates sustainable improvements in glycemic control. Diabetes 2000; 49(Suppl 1)A393
- Hay L C, Wilmshurst E G, Fulcher G. Unrecognized hypo- and hyperglycemia in well-controlled patients with type 2 diabetes mellitus: the results of continuous glucose monitoring. Diabetes Technol Therapeut 2003; 5: 19–26
- Bode B W, Gross T M, Thornton K R, Mastrototaro J J. Continuous glucose monitoring used to adjust diabetes therapy improves glycosylated hemoglobin: a pilot study. Diabetes Res Clin Pract 1999; 46: 183–90